Lee Financial’s Alnylam Pharmaceuticals ALNY Stock Holding History

Lee Financial’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-7	Closed	-$1K	–	759
2021 Q4	$1K	Buy	+7	New	+$1.3K	﹤0.01%	810

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lee Financial's ALNY Position: Q1 2022 in Review

Lee Financial sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2022, closing a stake of 7 shares — an estimated $1K sold.

Lee Financial first reported a position in ALNY in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 443 funds tracked by Wall St. Rank hold ALNY as of Q1 2022.

Lee Financial reported no remaining Alnylam Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Lee Financial sold 7 Alnylam Pharmaceuticals shares in Q1 2022, an estimated $1K.
Lee Financial first reported a position in Alnylam Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Lee Financial's Alnylam Pharmaceuticals position peaked at $1K in Q4 2021.
443 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2022.

Based on Lee Financial's 13F filing for Q1 2022, filed 11 May 2022.